SynShark Overview

  • Founded
  • 2013
  • Status
  • Private
  • Latest Deal Type
  • Conv. Debt
  • Latest Deal Amount
  • $213K
Latest Deal Amount
  • Investors
  • 1

SynShark General Information


Developer of a technology designed to biologically extract squalene from tobacco. The company's technology offers a method to extract squalene from tobacco plants instead of shark livers, which can be used for pharmaceutical products or can be refined into bio fuel, enabling pharmaceutical companies to create medicines using squalene.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Energy
Other Industries
Primary Office
  • 2013 Olde Regent Way
  • Suite 150-313
  • Leland, NC 28451
  • United States
+1 (713) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SynShark Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Convertible Debt 02-Mar-2017 $213K 00000 Completed Startup
2. Debt - General 11-Sep-2015 00000 00000 Completed Startup
1. Grant $5M Completed Startup
To view SynShark’s complete valuation and funding history, request access »

SynShark Executive Team (3)

Name Title Board Seat Contact Info
Jason Ornstein Executive Director
Yuan Dai Administrator
You’re viewing 2 of 3 executive team members. Get the full list »

SynShark Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arpa-E Government 000 0000 000000 0
To view SynShark’s complete investors history, request access »